Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial

Area of Science:

• Neuroscience
• Regenerative Medicine
• Clinical Trials

Background:

• Neuroinflammation is a key factor in Parkinson's disease (PD) progression and motor deficits.
• Allogeneic human mesenchymal stem cells (allo-hMSCs) show potential in mitigating neuroinflammation and improving motor symptoms in PD.

Purpose of the Study:

• To assess the efficacy of repeated intravenous doses of allo-hMSCs (10 × 10^6/kg) in enhancing motor function for patients with Parkinson's disease (PwP).

Main Methods:

• A phase 2, randomized, placebo-controlled trial involving 45 mild-to-moderate PwP.
• Participants received three allo-hMSC infusions, a mixed regimen (one placebo, two allo-hMSC), or three placebos at 18-week intervals.
• The primary outcome measured was a ≥5-point improvement in the MDS-UPDRS-III score at week 62, analyzed using Bayesian methods.

Main Results:

• The three-infusion group showed a greater proportion of participants with ≥5-point MDS-UPDRS-III improvement compared to placebo (93.7% PP).
• The two-infusion group demonstrated significantly less improvement than placebo (≥99.9% PP for difference).
• All treatment arms observed some improvement in MDS-UPDRS-III scores, with mild and transient adverse events.

Conclusions:

• Three allo-hMSC infusions effectively improved motor function in mild-to-moderate Parkinson's disease patients.
• Two infusions yielded less benefit than placebo, suggesting dose or variability issues.
• Future research should include functional potency assays to investigate batch-to-batch variability impacting allo-hMSC clinical efficacy.